SNU-1076 Xenograft Model Service for Head and Neck Cancer

The SNU-1076 cell line, derived from a human squamous cell carcinoma of the head and neck, offers a unique and highly relevant in vivo translational platform for exploring the biological mechanisms of upper aerodigestive tract malignancies and evaluating the therapeutic efficacy of novel anticancer interventions. As a specialized pre-clinical contract research organization, Alfa Cytology delivers a comprehensive, turnkey SNU-1076 Xenograft Model Service that integrates meticulous cell preparation with standardized in vivo protocols to streamline your head and neck oncology pipelines.

Overview of SNU-1076 Xenograft Model for Head and Neck Cancer

The SNU-1076 xenograft model serves as a highly characterized and biologically specific in vivo translation platform for preclinical investigation into HNSCC. Originally established from a primary squamous cell carcinoma of the larynx or upper aerodigestive mucosal pathways, transplanting these human cells into immunodeficient mouse hosts yields a reliable model that closely mirrors human clinical tumor architecture, local microenvironmental interactions, and characteristic vascularization.

Biologically, the SNU-1076 model is notable for its predictable engraftment parameters and steady growth kinetics, making it a dependable tool for managing rigid therapeutic screening timelines. It maintains key genetic profiles native to advanced squamous cell malignancies, such as dysregulated tumor suppressor mechanisms, specific cytokine expression patterns, and key cell-surface protein variations. These distinct pathophysiological features make the SNU-1076 model exceptionally valuable globally for assessing the therapeutic potency of novel cytotoxic chemotherapies, small-molecule signaling pathway inhibitors, monoclonal antibodies, and targeted radiotherapeutic combinations.

Fig 1. CD107a degranulation assay results for SNU-1041 MHC-IKO, SNU-1076, and Detroit-562. (Lee J, et al., 2023)

Cell Line Information: SNU-1076

The SNU-1076 cell line was established from a primary tumor lesion of a human head and neck squamous cell carcinoma. It displays an adherent, epithelial morphology during in vitro cultivation and serves as an excellent genetic proxy for upper aerodigestive tract oncology studies.

Our Services

Workflow of SNU-1076 Xenograft Model Construction

• Cell Culture & Quality Control: Human SNU-1076 cells are expanded in vitro utilizing certified nutrient growth media under optimized parameters. STR authentication and mycoplasma clearance verification are conducted prior to harvesting to guarantee phenotypic identity and biological purity.
• Host Selection & Acclimatization: Healthy, standardized immunocompromised mice (such as BALB/c Nude or NOD/SCID strains) are selected based on study designs. The animals are housed within controlled facility parameters for a designated adaptation period to establish stable physiological baselines.
• Precision Inoculation: A calibrated suspension of high-viability SNU-1076 cells is prepared and blended with a validated biological matrix carrier to improve spatial distribution. The mixture is precisely injected in vivo into the target cohorts via subcutaneous flank or orthotopic routes.
• Longitudinal Growth Tracking: Following successful model establishment and palpable tumor verification, tumor growth kinetics are tracked systematically using high-precision digital calipers. Animal body weights, physiological baselines, and general behavior are routinely cataloged.
• Stratification & Dosing: Once the expanding tumor volumes reach a predetermined, statistically optimal range, the animals are randomized into specific therapeutic cohorts. This stratification step ensures balanced baseline tumor parameters across all groups before customized dosing and efficacy evaluation protocols begin.

Fig 2. SNU-1076 Xenograft Model Construction Workflow

Case Study - SNU-1076 Xenograft Model Development

A preclinical validation study was conducted utilizing the SNU-1076 xenograft model to evaluate the therapeutic efficacy of a novel targeted agent designed for head and neck squamous cell carcinomas. Following precision subcutaneous inoculation of human SNU-1076 cells into immunodeficient mice, the tumors demonstrated steady, uniform engraftment and a highly predictable growth rate across the experimental cohorts. Animals assigned to the active treatment group exhibited a clear, statistically significant reduction in tumor volume compared to the vehicle control group, confirming the model's high sensitivity and robust predictive reliability for screening targeted head and neck oncology therapies.

Why Choose Alfa Cytology?

• Oncology Domain Expertise: Specialized knowledge in the cultivation and maintenance of diverse squamous cell carcinoma lineages, providing reliable in vivo platforms for complex head and neck cancer studies.
• Rigorous Quality Control: Stringent validation at every phase of in vitro and in vivo processing to completely eliminate confounding biological variables.
• Tailored Experimental Design: Flexible study frameworks accommodating custom mouse strain choices, specific dosing routes, and orthotopic or subcutaneous inoculation pathways.
• High-Resolution Deliverables: Every project concludes with a detailed, audit-ready data report providing comprehensive digital caliper metrics and robust statistical validations.

Contact us

Accelerating your head and neck oncology pipeline requires a preclinical partner with the technical proficiency to execute rigorous in vivo workflows flawlessly. If you are looking to advance your novel compound or require specialized preclinical testing utilizing the SNU-1076 platform, please reach out to us today to discuss your project layout with our scientific team.

For research use only. Not intended for any clinical use.